Amolyt Pharma
Amolyt Pharma, a clinical stage biotechnology company based in Lyon, France, is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Its development portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly.
Sector
Biopharmaceuticals
Strategy
Crossover
Website
amolytpharma.com
Related News
AstraZeneca closes acquisition of Amolyt Pharma
Amolyt Pharma granted FDA Fast Track Designation for eneboparatide for the treatment of hypoparathyroidism
Sofinnova Partners portfolio company Amolyt Pharma to be acquired by AstraZeneca
Amolyt Pharma enters into definitive agreement to be acquired by AstraZeneca
Amolyt Pharma announces initiation of phase 1 clinical trial of peptide growth hormone receptor antagonist (GHRA), AZP-3813, for Acromegaly
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.